Prenatal Gender Testing
VIAMEDEX'S ABSOLUTE GENDER IDENTITY TEST IS PROVEN BY THE DNAFFIRM TECHNOLOGY. IF THE FETAL Y CHROMOSOME IS EVIDENT IN A FEW DROPS OF MATERNAL BLOOD, THE MOTHER IS CARRYING A MALE FETUS. IF ONLY THE X CHROMOSOME IS PRESENT THE MOTHER IS CARRYING A FEMALE FETUS.
The VIAMEDEX Prenatal Gender Test is a non-invasive procedure that utilizes exclusive DNAffirm precision technology to genetically determine the gender of a fetus with 99% accuracy after approximately 8 weeks of gestation (or 10 weeks after the last period).
THIS TEST IS AVAILABLE IN EVERY COUNTRY
The extensive research done by VIAMEDEX using its exclusive DNAffirm technology in developing the Jack or Jill prenatal gender test has been essentially confirmed by recently published studies done at various medical schools.
Published studies have concluded that in 6500 tests performed on pregnant women the prenatal gender determination was 99.8% accurate.
You can have complete confidence in the VIAMEDEX Jack or Jill Prenatal Gender Test. The test is taken after 8 weeks of gestation, with 100% clinical precision, in a simple, non-invasive procedure. The test determines the presence (male) or absence (female) of the Y chromosome.
The gender of a fetus can be determined with 100% accuracy after approximately 8 weeks of gestation (10 weeks after the last missed period). At this stage of pregnancy, the maternal blood carries enough fetal DNA for identification of the gender of the fetus.
Gender identification is based on the specific identification of the Y chromosome which indicates that the fetus is absolutely a male, the absence of the Y chromosome indicates a female fetus. Results are obtained using a small blood sample taken from the mother's arm using the vacutainer tube we supply. The sample can be easily taken at any medical lab in just a few minutes. The sample is stabilized in the tube and returned to us by courier or mail.
Click here to order a sample collection kit at 1-877-842-4827. Results in 7 days, 99% accurate.
The VIAMEDEX genetic non-invasive Gender Determination Test has evolved since Lo et al., first described the presence of fetal DNA in maternal plasma and serum. The cell-free fetal DNA offered an important path for non-invasive prenatal gender determination. Based on a PCR assay, VIAMEDEX has determined that the concentration of fetal DNA in maternal plasma in the first trimester and particularly after 8 weeks of gestation was about 3.4%. It is estimated that a mean of 24.4 copies of fetal DNA circulates per ml. of maternal plasma. At this level, there is almost 100% precision in identifying the Y chromosome and establishing fetal gender.
Call toll free 1-877-842-4827 to order a sample collection kit by phone, or click here to order online.